BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 14578321)

  • 1. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil.
    Millán O; Brunet M; Campistol JM; Faura A; Rojo I; Vidal E; Jiménez O; Vives J; Oppenheimer F; Martorell J
    Clin Chem; 2003 Nov; 49(11):1891-9. PubMed ID: 14578321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations.
    Brunet M; Millán O; Jiménez O; Campistol JM; Vidal E; Rojo I; Oppenheimer F; Fortuna V; Martorell J
    Transplant Proc; 2004 Mar; 36(2 Suppl):437S-441S. PubMed ID: 15041382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil.
    Beckebaum S; Armstrong VW; Cicinnati VR; Streit F; Klein CG; Gerken G; Paul A; Oellerich M
    Ther Drug Monit; 2009 Apr; 31(2):205-10. PubMed ID: 19307937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
    Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
    Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.
    Mourad M; Malaise J; Chaib Eddour D; De Meyer M; König J; Schepers R; Squifflet JP; Wallemacq P
    Clin Chem; 2001; 47(7):1241-8. PubMed ID: 11427455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as does standard-dose cyclosporine in stable renal allografts.
    Grinyó JM; Cruzado JM; Millán O; Caldés A; Sabaté I; Gil-Vernet S; Serón D; Brunet M; Campistol JM; Torras J; Martorell J
    Transplantation; 2004 Nov; 78(9):1400-3. PubMed ID: 15548982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid.
    van Gelder T; Klupp J; Barten MJ; Christians U; Morris RE
    Ther Drug Monit; 2001 Apr; 23(2):119-28. PubMed ID: 11294511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
    Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis of chronic kidney disease after liver transplantation--experience from west China.
    Shao ZY; Yan LN; Wang WT; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
    World J Gastroenterol; 2012 Mar; 18(9):991-8. PubMed ID: 22408361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
    Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
    Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Best single time points to predict the area-under-the-curve in long-term heart transplant patients taking mycophenolate mofetil in combination with cyclosporine or tacrolimus.
    Mardigyan V; Giannetti N; Cecere R; Besner JG; Cantarovich M
    J Heart Lung Transplant; 2005 Oct; 24(10):1614-8. PubMed ID: 16210138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs-a short-term pilot study.
    Uchida J; Machida Y; Iwai T; Kuwabara N; Kabei K; Naganuma T; Kumada N; Kawashima H; Nakatani T
    Clin Transplant; 2014 Jan; 28(1):80-7. PubMed ID: 24329776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics.
    Kuriata-Kordek M; Boratynska M; Falkiewicz K; Porazko T; Urbaniak J; Wozniak M; Patrzalek D; Szyber P; Klinger M
    Transplant Proc; 2003 Sep; 35(6):2369-71. PubMed ID: 14529944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of mycophenolate mofetil in Omani patients on cyclosporine or tacrolimus.
    Mohsin N; Al-Raisi F; Militsala E; Kamble P; Abdel Razek E; Baddruddin M
    Transplant Proc; 2015 May; 47(4):1122-4. PubMed ID: 26036534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
    Cremers S; Schoemaker R; Scholten E; den Hartigh J; König-Quartel J; van Kan E; Paul L; de Fijter J
    Br J Clin Pharmacol; 2005 Sep; 60(3):249-56. PubMed ID: 16120063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
    Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
    Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.
    Park JM; Lake KD; Cibrik DM
    Ther Drug Monit; 2008 Oct; 30(5):591-6. PubMed ID: 18708992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.